Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 8/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130310 | 0.87 | CNR2 (0.58) | HRH3CNR2SCD | |
| SCHEMBL14387372 | 0.86 | HRH3 (0.41) | HRH3CNR2NPC1MAPTRAB9A | |
| SCHEMBL4292748 | 0.83 | SCD (0.50) | HRH3CNR2NPC1MAPTRAB9A | |
| SCHEMBL4143600 | 0.83 | CNR2 (0.47) | HRH3CNR2NPC1MAPTRAB9A | |
| SCHEMBL4125466 | 0.82 | OPRM1 (0.43) | CNR2NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4294013 | 0.82 | CNR2 (0.56) | HRH3CNR2 | |
| SCHEMBL4928039 | 0.82 | CNR2 (0.60) | HRH3CNR2NPC1MAPTRAB9A | |
| SCHEMBL4135808 | 0.81 | CNR2 (0.46) | HRH3CNR2MAPTSMN1; SMN2SCD | |
| SCHEMBL4288868 | 0.80 | CNR2 (0.58) | CNR2NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4935984 | 0.79 | CNR2 (0.38) | HRH3CNR2MAPTSCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | HRH3 1/4885CNR2 75/4885NPC1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.